- Conditions
- Non-Hodgkins Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Primary Central Nervous System Lymphoma
- Interventions
- Ublituximab
- Drug
- Lead sponsor
- TG Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 8
- States / cities
- Huntsville, Alabama • Jonesboro, Arkansas • Athens, Georgia + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 372
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma
- Interventions
- Bortezomib, Dexamethasone, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Rituximab, Temsirolimus
- Drug · Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 11
- States / cities
- Denver, Colorado • Atlanta, Georgia • Rochester, Minnesota + 7 more
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
- Interventions
- peripheral blood lymphocyte therapy
- Biological
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 1 Year to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2003
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
- Interventions
- Nemtabrutinib
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- ziv-aflibercept
- Biological
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 25 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, AML, Adult, CLL, CLL, Relapsed, CLL, Refractory
- Interventions
- Pitavastatin, Venetoclax
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Mucosa-Associated Lymphoid Tissue Lymphoma, Recurrent Follicular Lymphoma, Recurrent Hairy Cell Leukemia, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mucosa-Associated Lymphoid Tissue Lymphoma, Refractory Follicular Lymphoma, Refractory Hairy Cell Leukemia, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Small Lymphocytic Lymphoma
- Interventions
- Lenalidomide, Obinutuzumab, Oral Azacitidine
- Drug · Biological
- Lead sponsor
- Joseph Tuscano
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Cancer, Chronic Lymphocytic Leukemia, Diffuse Large Cell Lymphoma, Hematologic Malignancies, Hematology, Leukemia, Low Grade Lymphoma, Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma, Oncology, Oncology Patients, T Cell Lymphoma, Tumors
- Interventions
- AMG 319
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 3
- States / cities
- Hackensack, New Jersey • Durham, North Carolina • Salt Lake City, Utah
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Lymphoma, Non-Hodgkin (NHL), Acute Myeloid Leukemia (AML), Multiple Myeloma (MM)
- Interventions
- CAL-101
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 9
- States / cities
- Palo Alto, California • Baltimore, Maryland • Boston, Massachusetts + 6 more
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Prolymphocytic Leukemia, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
- Interventions
- arsenic trioxide, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Multiple Myeloma, Splenic Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma, Waldenström Macroglobulinemia
- Interventions
- alvocidib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Chronic Lymphocytic Leukemia, Richter Syndrome
- Interventions
- Duvelisib, Venetoclax
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 7
- States / cities
- Miami, Florida • Brewer, Maine • Boston, Massachusetts + 1 more
- Conditions
- Cancer
- Interventions
- fatigue assessment and management, management of therapy complications, psychosocial assessment and care
- Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 9
- States / cities
- Stanford, California • Denver, Colorado • Gainesville, Florida + 5 more
- Conditions
- Adult B Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Chronic Lymphocytic Leukemia, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Hepatosplenic T-Cell Lymphoma, Intraocular Lymphoma, Lymphomatous Involvement of Non-Cutaneous Extranodal Site, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Nodal Marginal Zone Lymphoma, Primary Cutaneous B-Cell Non-Hodgkin Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Small Intestinal Lymphoma, Splenic Marginal Zone Lymphoma, T-Cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenstrom Macroglobulinemia
- Interventions
- Alisertib, Laboratory Biomarker Analysis, Pharmacological Study, Vorinostat
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 5
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California + 2 more
- Conditions
- Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B-cell Lymphomas, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia
- Interventions
- Ublituximab, Lenalidomide
- Drug
- Lead sponsor
- TG Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 2
- States / cities
- Huntsville, Alabama • Bethesda, Maryland
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
- Interventions
- NX-5948
- Drug
- Lead sponsor
- Nurix Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Duarte, California • Los Angeles, California + 23 more
- Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Splenic Marginal Zone Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Nodal Marginal Zone Lymphoma, Refractory Splenic Marginal Zone Lymphoma
- Interventions
- Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Questionnaire Administration, Sonrotoclax, Zanubrutinib
- Procedure · Other · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
- Interventions
- ONO-7018
- Drug
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 11
- States / cities
- Santa Monica, California • Kansas City, Missouri • Florham Park, New Jersey + 7 more
- Conditions
- B-Cell Pediatric ALL
- Interventions
- Moxetumomab Pasudotox
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Los Angeles, California • Chicago, Illinois + 7 more
- Conditions
- Leukemia
- Interventions
- alemtuzumab, rituximab, fludarabine phosphate
- Biological · Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Jackson, Mississippi • New Brunswick, New Jersey + 1 more
- Conditions
- Leukemia, Lymphoma
- Interventions
- rituximab, epirubicin hydrochloride
- Biological · Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
- Interventions
- beclomethasone dipropionate
- Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 5 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL, MCL, Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma (MZL), Indolent B-cell Non-Hodgkin Lymphoma (iNHL), Aggressive B-cell Non-Hodgkin Lymphoma (aNHL)
- Interventions
- Epcoritamab
- Biological
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 666 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2029
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • San Francisco, California • Denver, Colorado + 14 more
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- cilengitide
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2001
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana